Investor relations
With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Press Releases
Sedana Medical AB’s Interim report January-June 2024
Regulatory
Enrolment of both US clinical trials completed, on track for first results in 2H.
Sedana Medical to acquire its main supplier to take control of supply chain and reduce cost of goods
Regulatory
Sedana Medical AB (publ) announces it has today entered into an agreement to acquire Innovatif Cekal…
Invitation to presentation of Sedana Medical’s interim report for the second quarter 2024
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the second quarter of 2024 on Tuesd…
Financial Calendar
| Annual General Meeting | 22 May 2024 | 14:00 |
| Interim Report Q2 2024 | 23 July 2024 | 07:00 |
